{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:47:04Z","timestamp":1794044824479,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Compass Pathways"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7\u2009kg\u2009m\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>2<\/jats:sup>\n                    ; s.d. 3.7) who met\n                    <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                    , Fifth Edition (DSM-5) criteria for AN or pAN (partial remission) were recruited to a study conducted at an academic clinical research institute. Participants received a single 25-mg dose of synthetic psilocybin in conjunction with psychological support. The primary aim was to assess safety, tolerability and feasibility at post-treatment by incidences and occurrences of adverse events (AEs) and clinically significant changes in electrocardiogram (ECG), laboratory tests, vital signs and suicidality. No clinically significant changes were observed in ECG, vital signs or suicidality. Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24\u2009h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. Participants\u2019 qualitative perceptions suggest that the treatment was acceptable for most participants. Results suggest that psilocybin therapy is safe, tolerable and acceptable for female AN, which is a promising finding given physiological dangers and problems with treatment engagement. ClinicalTrials.gov identifier\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04661514\">NCT04661514<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02455-9","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T12:01:51Z","timestamp":1690200111000},"page":"1947-1953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-9158","authenticated-orcid":false,"given":"Stephanie Knatz","family":"Peck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Gruen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-258X","authenticated-orcid":false,"given":"Kevin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Babakanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Trim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-7778","authenticated-orcid":false,"given":"Daphna M.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-4906","authenticated-orcid":false,"given":"Walter H.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2455_CR1","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMcp1803175","volume":"282","author":"J Mitchell","year":"2020","unstructured":"Mitchell, J. & Peterson, C. Anorexia nervosa. N. Engl. J. Med. 282, 1343\u20131351 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2455_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","volume":"68","author":"J Arcelus","year":"2011","unstructured":"Arcelus, J. et al. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch. Gen. Psychiatry 68, 724\u2013731 (2011).","journal-title":"Arch. Gen. Psychiatry"},{"key":"2455_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.chc.2008.07.013","volume":"18","author":"H Steinhausen","year":"2009","unstructured":"Steinhausen, H. Outcome of eating disorders. Child Adolesc. Psychiatr. Clin. N. Am. 18, 225\u2013242 (2009).","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"2455_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1176\/appi.ajp.159.8.1284","volume":"159","author":"HC Steinhausen","year":"2002","unstructured":"Steinhausen, H. C. The outcome of anorexia nervosa in the 20th century. Am. J. Psychiatry 159, 1284\u20131293 (2002).","journal-title":"Am. J. Psychiatry"},{"key":"2455_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jamapsychiatry.2020.4796","volume":"78","author":"W Kaye","year":"2021","unstructured":"Kaye, W. & Bulik, C. Treatment of patients with anorexia nervosa in the US\u2014a crisis in care. JAMA Psychiatry 78, 591\u2013592 (2021).","journal-title":"JAMA Psychiatry"},{"key":"2455_CR6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"M Madsen","year":"2019","unstructured":"Madsen, M. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmocology 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmocology"},{"key":"2455_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols, D. E. Psilocybin: from ancient magic to modern medicine. J. Antibiotics 73, 679\u2013686 (2020).","journal-title":"J. Antibiotics"},{"key":"2455_CR8","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1002\/eat.20109","volume":"37","author":"W Kaye","year":"2005","unstructured":"Kaye, W. et al. The neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems. Int J. Eat. Disord. 37, S15\u2013S19, discussion S20\u2013S21 (2005).","journal-title":"Int J. Eat. Disord."},{"key":"2455_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.tins.2013.01.003","volume":"36","author":"W Kaye","year":"2013","unstructured":"Kaye, W. et al. Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa. Trends Neurosci. 36, 110\u2013120 (2013).","journal-title":"Trends Neurosci."},{"key":"2455_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","volume":"36","author":"S Ling","year":"2022","unstructured":"Ling, S. et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs 36, 17\u201330 (2022).","journal-title":"CNS Drugs"},{"key":"2455_CR11","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1017\/S0033291721005493","volume":"53","author":"J Steding","year":"2023","unstructured":"Steding, J. et al. The effects of acute tryptophan depletion on instrumental reward learning in anorexia nervosa\u2014an fMRI study. Psychol. Med. 53, 3426\u20133436 (2023).","journal-title":"Psychol. Med."},{"key":"2455_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00406-022-01414-8","volume":"273","author":"T Weinert","year":"2023","unstructured":"Weinert, T. et al. No effects of acute tryptophan depletion on anxiety or mood in weight-recovered female patients with anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 273, 209\u2013217 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"2455_CR13","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.neubiorev.2022.104793","volume":"140","author":"M van Elk","year":"2022","unstructured":"van Elk, M. & Yaden, D. B. Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci. Biobehav. Rev. 140, 104793 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"2455_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett, F. S. et al. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci. Rep. 10, 2214 (2020).","journal-title":"Sci. Rep."},{"key":"2455_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","volume":"30","author":"A Garcia-Romeu","year":"2018","unstructured":"Garcia-Romeu, A. & Richards, W. A. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Intern. Rev. Psychiatry 30, 291\u2013316 (2018).","journal-title":"Intern. Rev. Psychiatry"},{"key":"2455_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268\u2013283, discussion 284\u2013292 (2006).","journal-title":"Psychopharmacology"},{"key":"2455_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1073\/pnas.1918477117","volume":"117","author":"M Forstmann","year":"2020","unstructured":"Forstmann, M. et al. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc. Natl Acad. Sci. USA 117, 2338\u20132346 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2455_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss, M. K. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl. Psychiatry 11, 574 (2021).","journal-title":"Transl. Psychiatry"},{"key":"2455_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14740338.2022.2047929","volume":"21","author":"J van Amsterdam","year":"2022","unstructured":"van Amsterdam, J. & van den Brink, W. The therapeutic potential of psilocybin: a systematic review. Expert Opin. Drug Saf. 21, 833\u2013840 (2022).","journal-title":"Expert Opin. Drug Saf."},{"key":"2455_CR20","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn (DSM-V) (American Psychiatric Association, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2455_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"2455_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"2455_CR23","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1176\/appi.ajp.161.12.2215","volume":"161","author":"W Kaye","year":"2004","unstructured":"Kaye, W. et al. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am. J. Psychiatry 161, 2215\u20132221 (2004).","journal-title":"Am. J. Psychiatry"},{"key":"2455_CR24","doi-asserted-by":"publisher","first-page":"101905","DOI":"10.1016\/j.cpr.2020.101905","volume":"81","author":"S Miles","year":"2020","unstructured":"Miles, S. et al. Cognitive flexibility in acute anorexia nervosa and after recovery: a systematic review. Clin. Psychol. Rev. 81, 101905 (2020).","journal-title":"Clin. Psychol. Rev."},{"key":"2455_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrn2682","volume":"10","author":"W Kaye","year":"2009","unstructured":"Kaye, W., Fudge, J. & Paulus, M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nat. Rev. Neurosci. 10, 573\u2013584 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"2455_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(13)61940-6","volume":"383","author":"C Bulik","year":"2014","unstructured":"Bulik, C. The challenges of treating anorexia nervosa. Lancet 383, 105\u2013106 (2014).","journal-title":"Lancet"},{"key":"2455_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean, K. A., Johnson, M. W. & Griffiths, R. R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J. Psychopharmacol. 25, 1453\u20131461 (2011).","journal-title":"J. Psychopharmacol."},{"key":"2455_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance, A. et al. Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J. Psychoactive Drugs 49, 427\u2013435 (2017).","journal-title":"J. Psychoactive Drugs"},{"key":"2455_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","volume":"149","author":"TD Brewerton","year":"2022","unstructured":"Brewerton, T. D. et al. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J. Psychiatr. Res. 149, 128\u2013135 (2022).","journal-title":"J. Psychiatr. Res."},{"key":"2455_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.amp.2021.08.004","volume":"179","author":"V Verroust","year":"2021","unstructured":"Verroust, V., Zafar, R. & Spriggs, M. Psilocybin in the treatment of anorexia nervosa: the English transition of a French 1959 case study. Annales M\u00e9dico-psychologiques revue psychiatrique 179, 777\u2013781 (2021).","journal-title":"Annales M\u00e9dico-psychologiques revue psychiatrique"},{"key":"2455_CR31","first-page":"102","volume":"5","author":"S Rodan","year":"2021","unstructured":"Rodan, S. et al. Psilocybin as a novel pharmacotherapy for treatment-refractory anorexia nervosa. OBM Neurobiol. 5, 102 (2021).","journal-title":"OBM Neurobiol."},{"key":"2455_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11920-022-01394-5","volume":"24","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan, N. et al. Psychedelic-assisted therapy for people with eating disorders. Curr. Psychiatry Rep. 24, 767\u2013775 (2022).","journal-title":"Curr. Psychiatry Rep."},{"key":"2455_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner, K. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168, 1266\u20131277 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"2455_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1098-108X(199412)16:4<363::AID-EAT2260160405>3.0.CO;2-#","volume":"16","author":"CG Fairburn","year":"1994","unstructured":"Fairburn, C. G. & Beglin, S. Assessment of eating disorders: interview or self-report questionnaire? Int. J. Eat. Disord. 16, 363\u2013370 (1994).","journal-title":"Int. J. Eat. Disord."},{"key":"2455_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-292","volume":"13","author":"K Halmi","year":"2013","unstructured":"Halmi, K. Perplexities of treatment resistance in eating disorders. BMC Psychiatry 13, 292 (2013).","journal-title":"BMC Psychiatry"},{"key":"2455_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/archinte.1990.00390160134027","volume":"150","author":"LM Rich","year":"1990","unstructured":"Rich, L. M. et al. Hypoglycemic coma in anorexia nervosa. Case report and review of the literature. Arch. Intern. Med. 150, 894\u2013895 (1990).","journal-title":"Arch. Intern. Med."},{"key":"2455_CR37","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.7326\/0003-4819-134-11-200106050-00011","volume":"134","author":"PS Mehler","year":"2001","unstructured":"Mehler, P. S. Diagnosis and care of patients with anorexia nervosa in primary care settings. Ann. Intern. Med. 134, 1048\u20131059 (2001).","journal-title":"Ann. Intern. Med."},{"key":"2455_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(20)30566-6","volume":"8","author":"M Solmi","year":"2021","unstructured":"Solmi, M. et al. Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis. Lancet Psychiatry 8, 215\u2013224 (2021).","journal-title":"Lancet Psychiatry"},{"key":"2455_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289\u2013299 (2015).","journal-title":"J. Psychopharmacol."},{"key":"2455_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., Garcia-Romeu, A. & Griffiths, R. R. Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug Alcohol Abuse 43, 55\u201360 (2017).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"2455_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481\u2013489 (2021).","journal-title":"JAMA Psychiatry"},{"key":"2455_CR42","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2455_CR43","doi-asserted-by":"publisher","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 284, 112749 (2020).","journal-title":"Psychiatry Res."},{"key":"2455_CR44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"M Spriggs","year":"2021","unstructured":"Spriggs, M., Kettner, H. & Carhart-Harris, R. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat. Weight Disord. 26, 1265\u20131270 (2021).","journal-title":"Eat. Weight Disord."},{"key":"2455_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/erv.2414","volume":"24","author":"J McClelland","year":"2016","unstructured":"McClelland, J. et al. Repetitive transcranial magnetic stimulation (rTMS) treatment in enduring anorexia nervosa: a case series. Eur. Eat. Disord. Rev. 24, 157\u2013163 (2016).","journal-title":"Eur. Eat. Disord. Rev."},{"key":"2455_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/erv.2766","volume":"28","author":"B Dalton","year":"2020","unstructured":"Dalton, B. et al. Repetitive transcranial magnetic stimulation treatment in severe, enduring anorexia nervosa: an open longer-term follow-up. Eur. Eat. Disord. Rev. 28, 773\u2013781 (2020).","journal-title":"Eur. Eat. Disord. Rev."},{"key":"2455_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/YCO.0000000000000739","volume":"34","author":"AE van Eeden","year":"2021","unstructured":"van Eeden, A. E., van Hoeken, D. & Hoek, H. W. Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Curr. Opin. Psychiatry 34, 515\u2013524 (2021).","journal-title":"Curr. Opin. Psychiatry"},{"key":"2455_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.chc.2019.05.012","volume":"28","author":"S Gorrell","year":"2019","unstructured":"Gorrell, S. & Murray, S. Eating disorders in males. Child Adolesc. Psychiatr. Clin. N. Am. 28, 641\u2013651 (2019).","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"2455_CR49","first-page":"2","volume":"4","author":"J Rucker","year":"2019","unstructured":"Rucker, J. et al. Psilocybin administration to healthy participants: safety and feasibility in a placebo-controlled study. Reflections 4, 2 (2019).","journal-title":"Reflections"},{"key":"2455_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","volume":"12","author":"Y Lecrubier","year":"1997","unstructured":"Lecrubier, Y., Sheehan, D. & Weiller, E. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur. Psychiatry 12, 224\u2013231 (1997).","journal-title":"Eur. Psychiatry"},{"key":"2455_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1521\/pedi.17.6.568.25355","volume":"17","author":"MC Zanarini","year":"2003","unstructured":"Zanarini, M. C. et al. A screening measure for BPD: the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD). J. Pers. Disord. 17, 568\u2013573 (2003).","journal-title":"J. Pers. Disord."},{"key":"2455_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31, 80\u201384 (1998).","journal-title":"Pharmacopsychiatry"},{"key":"2455_CR53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/eat.20931","volume":"45","author":"K Berg","year":"2012","unstructured":"Berg, K. et al. Psychometric evaluation of the eating disorder examination and eating disorder examination-questionnaire: a systematic review of the literature. Int. J. Eat. Disord. 45, 428\u2013438 (2012).","journal-title":"Int. J. Eat. Disord."},{"key":"2455_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/eat.23275","volume":"53","author":"PPP Machado","year":"2020","unstructured":"Machado, P. P. P. et al. Eating Disorder Examination-Questionnaire short forms: a comparison. Int. J. Eat. Disord. 53, 937\u2013944 (2020).","journal-title":"Int. J. Eat. Disord."},{"key":"2455_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6","volume":"2","author":"DM Garner","year":"1983","unstructured":"Garner, D. M., Olmstead, M. P. & Polivy, J. Development and validation of a multidimensional eating disorder inventory for anorexia and bulimia nervosa. Int. J. Eat. Disord. 2, 15\u201334 (1983).","journal-title":"Int. J. Eat. Disord."},{"key":"2455_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0887-6185(91)90032-O","volume":"5","author":"D Reed","year":"1991","unstructured":"Reed, D. et al. Development and validation of the physical appearance state and trait anxiety scale (PASTAS). J. Anxiety Disord. 5, 323\u2013332 (1991).","journal-title":"J. Anxiety Disord."},{"key":"2455_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/10640260290081678","volume":"10","author":"T Cash","year":"2002","unstructured":"Cash, T. et al. Beyond body image as a trait: the development and validation of the Body Image States Scale. Eat. Disord. 10, 103\u2013113 (2002).","journal-title":"Eat. Disord."},{"key":"2455_CR58","doi-asserted-by":"crossref","unstructured":"Spielberger, C. D. Manual for the State-Trait Anxiety Inventory (STAI) (Consulting Psychologists Press, 1983).","DOI":"10.1037\/t06496-000"},{"key":"2455_CR59","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/eat.22023","volume":"45","author":"D Bellace","year":"2012","unstructured":"Bellace, D. et al. The Yale-Brown-Cornell eating disorders scale self-report questionnaire: a new, efficient tool for clinicians and researchers. Int. J. Eat. Disord. 45, 856\u2013860 (2012).","journal-title":"Int. J. Eat. Disord."},{"key":"2455_CR60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.brat.2008.06.012","volume":"46","author":"K Bohn","year":"2008","unstructured":"Bohn, K. et al. The measurement of impairment due to eating disorder psychopathology. Behav. Res. Ther. 46, 1105\u20131111 (2008).","journal-title":"Behav. Res. Ther."},{"key":"2455_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jpsychires.2014.09.008","volume":"60","author":"TJ Reilly","year":"2015","unstructured":"Reilly, T. J. et al. Psychometric properties of the 16-item Quick Inventory of Depressive Symptomatology: a systematic review and meta-analysis. J. Psychiatr. Res. 60, 132\u2013140 (2015).","journal-title":"J. Psychiatr. Res."},{"key":"2455_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1037\/a0032539","volume":"25","author":"J Geller","year":"2013","unstructured":"Geller, J. et al. The psychometric properties of the Readiness and Motivation Questionnaire: a symptom-specific measure of readiness for change in the eating disorders. Psychol. Assess. 25, 759\u2013768 (2013).","journal-title":"Psychol. Assess."},{"key":"2455_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths, R. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 22, 621\u2013632 (2008).","journal-title":"J. Psychopharmacol."},{"key":"2455_CR64","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.brat.2009.11.001","volume":"48","author":"A Bardone-Cone","year":"2010","unstructured":"Bardone-Cone, A. et al. Defining recovery from an eating disorder: conceptualization, validation, and examination of psychosocial functioning and psychiatric comorbidity. Behav. Res. Ther. 48, 194\u2013202 (2010).","journal-title":"Behav. Res. Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02455-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:02:44Z","timestamp":1695628964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02455-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02455-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, the ClinicalTrials.gov ID was not included in the Abstract and is now amended in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.P. is a senior clinical consultant for Compass Pathways, the funder of the study, and receives compensation for this role. Additionally, she is a sub-investigator for an upcoming Compass-sponsored randomized trial evaluating psilocybin for anorexia nervosa and is a lead therapist for this trial and other Compass-sponsored trials. W.H.K. has served as a consultant and advisor for Compass Pathways, the funder of this study, and has received compensation for these roles. W.H.K. has also received financial support for this study and for an upcoming randomized controlled trial evaluating psilocybin for anorexia nervosa, which is sponsored by Compass Pathways. Additionally, he serves as site principal investigator for the upcoming referenced trial. S.S., T.G., K.Y., A.B., J.T. and D.F.M. report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}